Lakewood-Amedex’s Nu-3 Achieves Key Milestones Ahead of Phase 2 Trials for Diabetic Foot Ulcers
Nu-3 Formulation and Manufacturing Advances Set the Stage for Clinical Progress
Lakewood-Amedex Biotherapeutics (NASDAQ: LABT) announced it has completed crucial formulation, delivery, and manufacturing steps for its lead compound, Nu-3, a topical treatment aimed at infected diabetic foot ulcers (iDFU). These developments come as LABT prepares for upcoming Phase 2 clinical trials, underscoring an important step toward potentially introducing a much-needed antimicrobial therapy.
Manufacturing Efficiency and Stability Data Highlight R&D Strength
The company has successfully executed drug substance (active ingredient) and drug product (gel formulation) manufacturing at multikilogram scale, ensuring both cGMP compliance and high production efficiency. Notably, manufacturing process optimizations have led to an improved cost of goods while also delivering bulk Nu-3 material with superior physical and chemical characteristics.
Stability testing showed that Nu-3 bulk drug substance remains stable for at least 5 years, and the final gel formulation holds for at least 2 years. Moreover, bioburden testing found undetectable microbial contamination over two years, with antimicrobial effectiveness maintained without needing additional preservatives.
| Characteristic | Duration Demonstrated |
|---|---|
| Ingredient Stability (Bulk Drug) | 5 years |
| Product Stability (Gel) | 2 years |
| Undetectable Bioburden | 2 years |
| Preservatives Needed | No |
Unique Mechanism May Address Antimicrobial Resistance
Nu-3 and its broader Bisphosphocin® class offer a novel mechanism: pH- and concentration-dependent destabilization of bacterial cell membranes. This fast, broad-spectrum action is especially promising in reducing threats from antibiotic-resistant bacteria, such as MRSA and VRE. Early clinical exploration revealed positive trends in safety and antimicrobial response, as well as wound healing. No significant safety signals were observed during subclinical dosing.
Positive Early Data Underpins Upcoming Phase 2 Trials
With the foundational clinical and process data in place, Lakewood-Amedex plans to launch an initial Phase 2a safety and dose response trial, followed by a larger placebo-controlled Phase 2b study. Both will help establish the most effective dosing regimen for Nu-3 gel in treating mildly infected diabetic foot ulcers and serve as a springboard toward potential approval in broader indications, including complicated urinary tract and pulmonary infections.
Takeaway: Expanding Horizons in Antimicrobial Innovation
Lakewood-Amedex’s achievements with Nu-3 mark more than just an R&D milestone—they reflect real progress toward addressing both clinical needs in diabetic wound care and global challenges posed by antimicrobial resistance concerns. As Phase 2 trials approach, Nu-3’s robust formulation, long-term stability, and broad-spectrum potential may set LABT apart as both a scientific innovator and a potential leader in infection therapeutics. Investors and healthcare watchers will no doubt be monitoring the next stage of Nu-3’s clinical journey.
Contact Information:
If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.
About the Publisher - Marketchameleon.com:
Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.
NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.
The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.
Disclosure: This article was generated with the assistance of AI